Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

Uro-Oncology

Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer

Prostate Cancer Prostatic Dis.

Nair SM, Peters M, Kurver P, Lavi A, Verhoeff JJC, van der Voort van Zyp JRN, van Son MJ, Chin JL

doi: 10.1038/s41391-020-00265-5.

Erectile and Sexual Functions and DysfunctionsUrinary IncontinenceUro-Oncology

Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade

Cancer Med.

Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL

doi: 10.1002/cam4.1103.

Uro-Oncology

Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought

Eur Urol.

Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A

doi: 10.1016/j.eururo.2020.06.043.

Further Publications Urology

Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials

Prostate Cancer Prostatic Dis

Jiang T, Markovic D, Patel J, Juarez JE, Ma TM, Shabsovich D, Nickols NG, Reiter RE, Elashoff D, Rettig MB, Zaorsky NG, Spratt DE, Kishan AU

doi: 10.1038/s41391-021-00432-2

Uro-Oncology

Exercise-induced attenuation of treatment side-effects in newly diagnosed prostate cancer patients beginning androgen deprivation therapy: a randomised controlled trial

BJU Int.

Ndjavera W, Orange ST, O'Doherty AF, Leicht AS, Rochester M, Mills R, Saxton JM

doi: 10.1111/bju.14922.

Uro-Oncology

Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry

Eur Urol.

Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR

doi: 10.1016/j.eururo.2019.07.012.

Uro-Oncology

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

Eur Urol.

Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ

doi: 10.1016/j.eururo.

Uro-Oncology

Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study

Prostate.

Lundgren PO, Kjellman A, Norming U, Gustafsson O

doi: 10.1002/pros.23991.

Uro-Oncology

Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist

Prostate Cancer Prostatic Dis.

Margel D, Ber Y, Peer A, Shavit-Grievink L, Pinthus JH, Witberg G, Baniel J, Kedar D, Rosenbaum E

doi: 10.1038/s41391-020-0264-9.

Related content

Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer

Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade

Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought

Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials

Exercise-induced attenuation of treatment side-effects in newly diagnosed prostate cancer patients beginning androgen deprivation therapy: a randomised controlled trial

Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study

Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist